HALO logo
halo search icon
Taysha Gene Therapies, Inc.

US$5.49

Price Change Indicator
0.31 (5.88%)
Taysha Gene Therapies, Inc.
TSHA · NAS

Taysha Gene Therapies, Inc.

Start Trading TSHA for Free

US$5.49

Price Arrow0.31 (5.88%)
20/05/2026 04:00:00 PM
All-CompaniesAll-ConsensusBig CandleExtreme Oversold (Realtime)HALO AllHALO Consensus Value
Consensus Score
Lock Icon/10
Recommend
Lock
Target Price
Lock
Deviation
Lock
Unlock Full Consensus Insights

Taysha Gene Therapies, Inc. Overview

TSHA Health Scores

Short Term

Mean Reversion

Neutral

Trend

Neutral

Event

Neutral

HALO Model

Mqv

Very Weak

Garp

Very Weak

Mqv Small

Neutral

Valuation

Value

Lock Icon

Consensus

Lock Icon

Momentum

Price

Weak

Earnings

Weak

Growth

Earnings

Very Weak

Dividends

Very Weak

Quality

Capital Efficiency

Very Weak

Balance Sheet

Very Weak

About TSHA

icon
icon

Telephone

1.214.612.0000

icon

Address

Suite 1430, 3000 Pegasus Park Drive, Dallas, TX 75247

Description

Taysha Gene Therapies, Inc. is a clinical-stage biotechnology company, which engages in the development and commercialization of adeno-associated viruses (AAV) based gene therapies for the treatment of monogenic diseases of the central nervous system. It also develops multiple gene therapy platforms which include AAV9 Discovery, Novel Capsid, and AAV Redosing. The company was founded by Steven Gray, Berge Minassian, and R. A. Session II in 2019 and is headquartered in Dallas, TX.

TSHA Price Chart

Key Stats

Market Cap

US$1.49B

PE

0.00

EV/EBITDA

N/A

Dividends Overview

DIV Yield

0%

Franking

0%

Ex Dividend Date (est.)

N/A

Market Data

52 weeks range

Low 2.25 - 7.3

Trade Value (12mth)

US$4,126,830.00

1 week

-13%

1 month

-16.64%

YTD

-1.24%

1 year

79.41%

All time high

33.35

Key Fundamentals

EPS 3 yr Growth

-91.00%

EBITDA Margin

NaN%

Operating Cashflow

-$93m

Free Cash Flow Return

-41.50%

ROIC

-48.60%

Interest Coverage

NaN

Quick Ratio

12.20

Other Data

Shares Outstanding (Fully Diluted)

367m

HALO Sector

Healthcare

Next Company Report Date

03-Mar-27

Next Ex Dividend Date

N/A

Next Dividend Pay Date

N/A

Reporting Currency

USD

Short Sell (% of issue)

0.00

TSHA Announcements

Latest Announcements

DateAnnouncements
06 May 26
06 May 26
06 May 26
19 March 26
19 March 26

TSHA Fundamentals

Per Share Records

Historical data

Forecast data

USD2021202220232024202320242025202620272028
Per Share, Growth & Valuations
EPS (Basic)
 $locklocklocklock-0.96-0.36-0.34locklocklock
EPS (Fully Diluted)
 $locklocklocklock-0.96-0.36-0.34locklocklock
Growth
 %locklocklocklock74.662.84.5locklocklock
PE
 XlocklocklocklockN/AN/AN/Alocklocklock
EV/EBITDA
 XlocklocklocklockN/AN/AN/Alocklocklock

Dividends

Key Stats

Ex Dividend Date (est.)

N/A

DIV Yield

0%

Franking Level

0%

DPSg

N/A

Quality Yield

lock

Falling Divs over next 2

lock

Want to learn more?Frequently asked questions.
What is the current share price of Taysha Gene Therapies, Inc. (TSHA:NAS)?
Halo FAQ
The current share price of Taysha Gene Therapies, Inc. (TSHA:NAS) is USD$5.49.
What is the 52-week high share price for Taysha Gene Therapies, Inc. (TSHA:NAS)?
Halo FAQ
The 52-week high share price for Taysha Gene Therapies, Inc. (TSHA:NAS) is USD$7.30.
What is the 52-week low share price for Taysha Gene Therapies, Inc. (TSHA:NAS)?
Halo FAQ
The 52-week low share price for Taysha Gene Therapies, Inc. (TSHA:NAS) is USD$2.25.
What is the dividend yield for Taysha Gene Therapies, Inc. (TSHA:NAS)?
Halo FAQ
Taysha Gene Therapies, Inc. (TSHA:NAS) does not pay a dividend.
What was Taysha Gene Therapies, Inc. (TSHA:NAS) last dividend payment?
Halo FAQ
Taysha Gene Therapies, Inc. (TSHA:NAS) does not pay a dividend.
What is the franking level for Taysha Gene Therapies, Inc. (TSHA:NAS)?
Halo FAQ
Taysha Gene Therapies, Inc. (TSHA:NAS) has a franking level of 0.00%.
In which sector is Taysha Gene Therapies, Inc. (TSHA:NAS) classified?
Halo FAQ
Taysha Gene Therapies, Inc. (TSHA:NAS) is classified in the Healthcare.

See beyond the curve.

One solution for research, investing and portfolio management.
Start FREE Trial